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Safety and efficacy of heparin-bonded surfaces in
cardiopulmonary bypass
Ludwig K. von Segesser, MD, FETCS, FACS
The first article on heparin surface bonding was published in 1963 byGott, Whiffen, and Datton.1 At that time, the development of blood-exposed surfaces with improved thromboresistance was of primeinterest. In those days, device occlusion during cardiopulmonarybypass (CPB) was a current problem. The presence of a shunt linethat allows the arterial filter to be bypassed in most CPB circuits is
still a testament to this major weakness of perfusion. Fortunately, in the early days
the arterial filters tended to thrombose before the heat exchangers and oxygenators,
and bypassing them usually salvaged the procedure. However, increasing awareness
of this problem led to the development of more thromboresistant arterial filters with
a variety of heparin surface coatings. The success of these efforts opened the door
for systematic application of heparin surface coatings for filter screens at various
positions in the CPB circuit. Routine clinical use of heparin-coated components was
thus established. The practice remained unrecognized for many years because CPB
appeared to be extremely safe in conjunction with full systemic heparinization as
defined by an activated coagulation time (ACT) of more than 480 seconds.
Use of heparin-coated equipment for perfusion with low or no systemic hepa-
rinization again goes back to Gott, who introduced the Gott shunt for bypassing
blood during repair of aneurysms of the descending thoracic aorta. This approach,
which was adopted by many surgeons, provided evidence that perfusion devices did
not require full systemic heparinization if their design and surface properties were
adequate. However, almost 30 years of step-by-step development2 were necessary to
get access to the tip-to-tip heparin-coated CPB circuit that allowed, first, partial and,
later, total CPB3 with low systemic heparin levels similar to those used in vascular
surgery (ACT 180 seconds). Even though a number of studies have demonstrated
reduced blood loss and transfusion requirements after CPB with heparin-coated
equipment and low systemic heparinization,4,5 this issue remains the subject of
controversy.
In parallel, many groups documented that heparin surface coating of perfusion
equipment reduced the perfusion-induced inflammatory response.6 These findings
may be less striking in the clinical setting with full systemic heparinization, because
of the significant noise level resulting from cardiotomy suction7 and other ancillary
equipment. However, increasing evidence shows that heparin-coated perfusion
equipment is beneficial, despite full systemic heparinization. Wahba and colleagues8
have demonstrated significant reduction of transoxygenator/heat exchanger pressure
gradients for various heparin-coated devices as compared with uncoated devices
during routine cardiac surgery. These findings suggest that the pressures between the
main pump and the oxygenator/heat exchanger structure often reach critical levels
in current clinical practice in which uncoated perfusion equipment is used. This
phenomenon usually is unnoticed because the arterial pressure is not usually
measured anterior to the oxygenator/heat exchanger structure. Obviously, routine
CPB is still far from perfect.
Once more, Øvrum and colleagues have provided an important piece of work in
this setting. Their most recent study9 involves 1336 patients undergoing routine
coronary bypass with either Duraflo II (Baxter Healthcare Corp, Bentley Labora-
tories Division, Irvine, Calif) or Carmeda BioActive Surface (CBAS; Medtronic
Inc, Minneapolis, Minn) heparin-coated CPB equipment with low systemic hepa-
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rinization (ACT  250 seconds). The 2 heparin coatings
studied have very different histories, are chemically differ-
ent, and are bonded differently. Baseline patient parameters
and outcomes look similar for the 2 patient groups analyzed.
The patients with Duraflo II–coated CPB equipment re-
quired less systemic heparin to maintain the target ACT
than did the patients with CBAS-coated CPB equipment.
Interestingly enough, patients in the Duraflo II group also
required less protamine for neutralization of circulating
heparin than did patients in the CBAS group. The authors
suggest that heparin leakage from the Duraflo II coating,
which is more common than leakage from the CBAS coat-
ing, can explain this finding. However, if free heparin orig-
inating from the coating would have to be neutralized to-
gether with injected heparin, thus completing the total
amount of circulating heparin necessary to reach a certain
target ACT, one would expect to see no difference for
protamine requirements between the 2 groups analyzed.
Alternatively, a higher rate of antithrombin III adsorption
onto the CBAS coating can explain higher requirements for
both circulating heparin and then protamine as compared
with the Duraflo II group.
Other mechanisms are involved as well, but this theoret-
ical discussion should not divert our attention from the fact
that Øvrum and colleagues9 have operated on a substantial
number of patients (1336) who underwent routine coronary
bypass grafting with low systemic heparinization and no
oxygenator obstruction. Their achievements include 4.6 
1.3 distal anastomoses per patient, at least 1 internal tho-
racic artery anastomosis in 99.3% of the patients, homolo-
gous transfusions in only 4.3% of the patients, and a hos-
pital mortality of 0.3% (4/1336 patients)! If this was the
standard of care on January 1, 2000, the rest of us doing
CPB operations, as well as those involved in blood banking,
are facing a major challenge.
Of course, one has to be aware of the disadvantages of
perfusion with low systemic heparinization despite the use
of heparin-coated equipment (eg, potential for device oc-
clusion, stroke) and the technical hints to avoid them.3
However, to give this approach a fair trial, one must also
consider the disadvantages of full systemic heparinization
(eg, bleeding, homologous transfusion, transfusion-related
infection with regularly updated additional microorgan-
isms). Hence, although the CPB philosophy selected for a
specific patient (full versus low systemic heparinization) is
a tradeoff, it becomes more and more apparent that, effec-
tively, there is no free ride!
References
1. Gott VL, Whiffen JD, Datton RC. Heparin surface bonding on col-
loidal graphite surface. Science. 1963:142;1297-8.
2. von Segesser LK, Weiss BM, Turina MI. Perfusion with heparin-
coated equipment: potential for clinical use. Sem Thorac Cardiovasc
Surg. 1990;2:373-80.
3. von Segesser LK, Weiss BM, Pasic M, Garcia E, Turina MI. Risk and
benefit of low systemic heparinization during open heart surgery. Ann
Thorac Surg. 1994;58:391-8.
4. Aldea GS, Doursounian BA, O’Gara P, Treanor P, Shapira OM, Lazar
HL, et al. Heparin bonded circuits with a reduced anticoagulation
protocol in primary CABG: a prospective, randomized study. Ann
Thorac Surg. 1996;62:410-8.
5. Øvrum E, A˚ m Holen E, Tangen G, Brosstad F, Abdelnoor M, Ringdal
AML, et al. Completely heparinized cardiopulmonary bypass and
reduced systemic heparin: clinical and hemostatic effects. Ann Thorac
Surg. 1995;60:365-71.
6. Videm V, Svennevig JL, Fosse E, Semb G, Østerud A, Mollnes TE.
Reduced complement activation with heparin-coated oxygenator and
tubings in coronary bypass operations. J Thorac Cardiovasc Surg.
1992;103:806-13.
7. Tevaearai HT, Mueller XM, Horisberger J, Augstburger M, Bock H,
Knorr A, et al. In situ control of cardiotomy suction reduces blood
trauma. ASAIO J. 1998;44:M380-3.
8. Wahba A, Philipp A, Behr R, Birnbaum DE. Heparin coated equip-
ment reduces the risk of oxygenator failure. Ann Thorac Surg. 1998;
65:1310-2.
9. Øvrum E, Tangen G, Øystese R, Ringdal MAL, Istad R. Comparison
of two heparin-coated extracorporeal circuits with reduced systemic
anticoagulation in routine coronary artery bypass operations. J Thorac
Cardiovasc Surg. 2001;121:324-30.
von Segesser Editorials
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 3 S91
